IMNN (Imunon) Cyclically Adjusted PS Ratio: (As of Jul. 12, 2026)


IMNN Imunon Inc IMNN
26 GF Score
Price $2.07
! 3 Warning Signs
View Full Analysis

What is Imunon Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Imunon  (NAS:IMNN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Imunon Cyclically Adjusted PS Ratio Related Terms


Imunon Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Imunon's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imunon Cyclically Adjusted PS Ratio Chart

Imunon Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.72 0.47 0.00 0.00 0.00

Imunon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IMNN vs KAPA, HCWB, CURX: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Imunon's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imunon Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Imunon's Cyclically Adjusted PS Ratio falls into.


IMNN
26GF Score
Imunon Inc IMNN
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imunon Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Imunon's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Imunon's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Imunon Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 13.889 241.018 19.029
201609 12.500 241.428 17.097
201612 12.500 241.432 17.097
201703 13.889 243.801 18.812
201706 3.676 244.955 4.955
201709 3.049 246.819 4.079
201712 1.420 246.524 1.902
201803 1.389 249.554 1.838
201806 1.374 251.989 1.801
201809 1.374 252.439 1.797
201812 1.359 251.233 1.786
201903 1.276 254.202 1.658
201906 1.190 256.143 1.534
201909 1.126 256.759 1.448
201912 0.947 256.974 1.217
202003 0.947 258.115 1.212
202006 0.817 257.797 1.046
202009 0.718 260.280 0.911
202012 0.644 260.474 0.816
202103 0.947 264.877 1.181
202106 0.285 271.696 0.346
202109 0.283 274.310 0.341
202112 0.282 278.802 0.334
202203 0.283 287.504 0.325
202206 0.234 296.311 0.261
202209 0.230 296.808 0.256
202212 0.187 296.797 0.208
202303 0.000 301.836 0.000
202306 0.000 305.109 0.000
202309 0.000 307.789 0.000
202312 0.000 306.746 0.000
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 0.000 315.605 0.000
202503 0.000 319.799 0.000
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Imunon Business Description

Other Exchanges CBO0:Germany
Address 997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
26GF Score

Get the complete analysis for IMNN

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.07
Price